These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33849283)

  • 1. Recent advances in β-catenin/BCL9 protein-protein interaction inhibitors.
    Zhang H; Bao Y; Liu C; Li J; Zhu D; Zhang Q
    Future Med Chem; 2021 May; 13(10):927-940. PubMed ID: 33849283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of β-catenin/B cell lymphoma 9 protein-protein interaction using α-helix-mimicking sulfono-γ-AApeptide inhibitors.
    Sang P; Zhang M; Shi Y; Li C; Abdulkadir S; Li Q; Ji H; Cai J
    Proc Natl Acad Sci U S A; 2019 May; 116(22):10757-10762. PubMed ID: 31088961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 2-(3-(3-Carbamoylpiperidin-1-yl)phenoxy)acetic Acid Derivatives as Novel Small-Molecule Inhibitors of the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
    Wang Z; Zhang M; Luo W; Zhang Y; Ji H
    J Med Chem; 2021 May; 64(9):5886-5904. PubMed ID: 33902288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of small molecule inhibitors of the Wnt/β-catenin signaling pathway by targeting β-catenin/Tcf4 interactions.
    Yan M; Li G; An J
    Exp Biol Med (Maywood); 2017 Jun; 242(11):1185-1197. PubMed ID: 28474989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 1-Benzoyl 4-Phenoxypiperidines as Small-Molecule Inhibitors of the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
    Li Z; Zhang M; Teuscher KB; Ji H
    J Med Chem; 2021 Aug; 64(15):11195-11218. PubMed ID: 34270257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of an Orally Bioavailable Small-Molecule Inhibitor for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
    Wang Z; Zhang M; Quereda V; Frydman SM; Ming Q; Luca VC; Duckett DR; Ji H
    J Med Chem; 2021 Aug; 64(16):12109-12131. PubMed ID: 34382808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Novel 1-Phenylpiperidine Urea-Containing Derivatives Inhibiting β-Catenin/BCL9 Interaction and Exerting Antitumor Efficacy through the Activation of Antigen Presentation of cDC1 Cells.
    Zhu W; Liu C; Xi K; Li A; Shen LA; Li Y; Jia M; He Y; Chen G; Liu C; Chen Y; Chen K; Sun F; Zhang D; Duan C; Wang H; Wang D; Zhao Y; Meng X; Zhu D
    J Med Chem; 2024 Aug; 67(15):12485-12520. PubMed ID: 38912577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling.
    Takada K; Zhu D; Bird GH; Sukhdeo K; Zhao JJ; Mani M; Lemieux M; Carrasco DE; Ryan J; Horst D; Fulciniti M; Munshi NC; Xu W; Kung AL; Shivdasani RA; Walensky LD; Carrasco DR
    Sci Transl Med; 2012 Aug; 4(148):148ra117. PubMed ID: 22914623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct targeting of β-catenin in the Wnt signaling pathway: Current progress and perspectives.
    Wang Z; Li Z; Ji H
    Med Res Rev; 2021 Jul; 41(4):2109-2129. PubMed ID: 33475177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the interaction of BCL9 with beta-catenin and development of fluorescence polarization and surface plasmon resonance binding assays for this interaction.
    Kawamoto SA; Thompson AD; Coleska A; Nikolovska-Coleska Z; Yi H; Wang S
    Biochemistry; 2009 Oct; 48(40):9534-41. PubMed ID: 19715304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the β-Catenin Coactivator BCL9-2 in Breast Cancer Cells.
    El-Hage P; Petitalot A; Monsoro-Burq AH; Maczkowiak F; Driouch K; Formstecher E; Camonis J; Sabbah M; Bièche I; Lidereau R; Lallemand F
    Mol Cancer Res; 2015 May; 13(5):902-12. PubMed ID: 25678599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOX7 Suppresses Wnt Signaling by Disrupting β-Catenin/BCL9 Interaction.
    Fan R; He H; Yao W; Zhu Y; Zhou X; Gui M; Lu J; Xi H; Deng Z; Fan M
    DNA Cell Biol; 2018 Feb; 37(2):126-132. PubMed ID: 29271667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LATS2 suppresses oncogenic Wnt signaling by disrupting β-catenin/BCL9 interaction.
    Li J; Chen X; Ding X; Cheng Y; Zhao B; Lai ZC; Al Hezaimi K; Hakem R; Guan KL; Wang CY
    Cell Rep; 2013 Dec; 5(6):1650-63. PubMed ID: 24360964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-Based Optimization of Small-Molecule Inhibitors for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
    Zhang M; Wang Z; Zhang Y; Guo W; Ji H
    J Med Chem; 2018 Apr; 61(7):2989-3007. PubMed ID: 29566337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating T
    Feng M; Jin JQ; Xia L; Xiao T; Mei S; Wang X; Huang X; Chen J; Liu M; Chen C; Rafi S; Zhu AX; Feng YX; Zhu D
    Sci Adv; 2019 May; 5(5):eaau5240. PubMed ID: 31086813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted disruption of the BCL9/β-catenin interaction by endosomal-escapable nanoparticles functionalized with an E-cadherin-derived peptide.
    Yang G; Zhang J; You W; Zhao X; Hou P; He W; Yan J; Guo H
    Nanotechnology; 2020 Mar; 31(11):115102. PubMed ID: 31751960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizations of a novel fluorescence polarization-based high-throughput screening assay for β-catenin/LEF1 interaction inhibitors.
    Chen Y; Fu Z; Li D; Yue Y; Liu X
    Anal Biochem; 2021 Jan; 612():113966. PubMed ID: 32956692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of triazole-stapled BCL9 α-helical peptides to target the β-catenin/B-cell CLL/lymphoma 9 (BCL9) protein-protein interaction.
    Kawamoto SA; Coleska A; Ran X; Yi H; Yang CY; Wang S
    J Med Chem; 2012 Feb; 55(3):1137-46. PubMed ID: 22196480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interactions of Bcl9/Bcl9L with β-catenin and Pygopus promote breast cancer growth, invasion, and metastasis.
    Vafaizadeh V; Buechel D; Rubinstein N; Kalathur RKR; Bazzani L; Saxena M; Valenta T; Hausmann G; Cantù C; Basler K; Christofori G
    Oncogene; 2021 Oct; 40(43):6195-6209. PubMed ID: 34545187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCL9 promotes epithelial mesenchymal transition and invasion in cisplatin resistant NSCLC cells via β-catenin pathway.
    Zhang Y; Zhang Q; Chen H; Wang C
    Life Sci; 2018 Sep; 208():284-294. PubMed ID: 30009824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.